2021
Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis
Reich K, Mrowietz U, Menter A, Griffiths C, Bagel J, Strober B, Gomez N, Shi R, Guerette B, Lebwohl M. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. Journal Of The European Academy Of Dermatology And Venereology 2021, 35: 2409-2414. PMID: 34255891, DOI: 10.1111/jdv.17520.Peer-Reviewed Original ResearchConceptsDermatology Life Quality IndexWeek 32Treatment targetsPooled analysisNail Psoriasis Severity IndexGlobal assessmentPhysician global assessmentSevere plaque psoriasisBaseline disease severitySeverity IndexPsoriasis Severity IndexLong-term outcomesLife Quality IndexSevere skin diseaseImportant clinical conceptsESTEEM 1Plaque psoriasisDisease durationMost patientsPsoriasis AreaModerate diseasePsoriasis severityDisease characteristicsPsoriasis guidelinesSubgroup analysis
2005
Alefacept in the treatment of psoriatic nail disease: A small case series
Cassetty C, Alexis A, Shupack J, Strober B. Alefacept in the treatment of psoriatic nail disease: A small case series. Journal Of The American Academy Of Dermatology 2005, 52: 1101-1102. PMID: 15928640, DOI: 10.1016/j.jaad.2005.01.101.Peer-Reviewed Original Research
2003
Pachyonychia congenita, type II.
Strober B. Pachyonychia congenita, type II. Dermatology Online Journal 2003, 9: 12. PMID: 14594585, DOI: 10.5070/d31c23k0nn.Peer-Reviewed Original ResearchConceptsClinical presentation